2.59

1.89% -0.05

X 4 Pharmaceuticals Inc (XFOR)

Overview News Price History Option Chain Financials Discussions Forecast Stock Split

X 4 Pharmaceuticals Inc stock is traded at $2.59, with a volume of 967.58K. It is down -1.89% in the last 24 hours and down -26.21% over the past month. X4 Pharmaceuticals Inc is a biopharmaceutical company developing and commercializing novel therapeutics for the treatment of rare hematology diseases. The Company's clinical candidate is mavorixafor, a small molecule antagonist of the chemokine receptor CXCR4 that is being developed as an oral, once-daily therapy. It can increase the mobilization of mature, functional white blood cells from the bone marrow into the bloodstream. It also has two pre-clinical candidates X4P-003 and X4P-002 which are CXCR4 antagonists with different properties.

Previous Close:

$2.64

Open:

$2.64

24h Volume:

967.58K

Relative Volume:

1.56

Market Cap:

$256.79M

Revenue:

$9.01M

Net Income/Loss:

$-99.72M

P/E Ratio:

-0.5707

EPS:

-4.5381

Net Cash Flow:

$-92.85M

1W Performance:

-11.00%

1M Performance:

-26.21%

6M Performance:

-37.44%

1Y Performance:

-12.79%

1-Day Range:

$2.52

$2.71

1-Week Range:

$2.43

$2.93

52-Week Range:

$2.43

$4.83

X 4 Pharmaceuticals Inc Stock (XFOR) Company Profile

Name

X 4 Pharmaceuticals Inc

Sector

Healthcare (1052)

Industry

Biotechnology (594)

Phone

857-529-8300

Address

61 NORTH BEACON STREET, BOSTON, MA

Employee

Twitter

@x4pharma

Next Earnings Date

2026-11-04

Latest SEC Filings

XFOR's Discussions on Twitter

Compare XFOR vs VRTX, MRNA, REGN, ARGX, ONC

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
XFOR X 4 Pharmaceuticals Inc	2.59	256.79M	9.01M	-99.72M	-92.85M	-4.5381
VRTX Vertex Pharmaceuticals Inc	499.74	126.66B	12.34B	4.34B	3.71B	16.87
MRNA Moderna Inc	218.01	87.04B	2.23B	-3.19B	-1.60B	-8.1462
REGN Regeneron Pharmaceuticals Inc	790.74	81.41B	14.92B	4.42B	3.79B	41.04
ARGX Argen X Se Adr	819.14	51.51B	4.16B	1.29B	734.26M	19.58
ONC Beone Medicines Ltd Adr	369.06	41.75B	5.76B	514.49M	1.10B	4.4813

X 4 Pharmaceuticals Inc Stock (XFOR) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Jul-10-26	Initiated	Wells Fargo	Overweight
Jun-02-26	Initiated	Leerink Partners	Outperform
Mar-09-26	Initiated	Guggenheim	Buy
Dec-05-25	Resumed	Stifel	Buy
Dec-12-23	Downgrade	B. Riley Securities	Buy → Neutral
Aug-30-23	Resumed	B. Riley Securities	Buy
Dec-22-22	Initiated	Cantor Fitzgerald	Overweight
Dec-12-22	Initiated	Piper Sandler	Overweight
Dec-23-19	Initiated	Oppenheimer	Outperform
Dec-18-19	Initiated	ROTH Capital	Buy
Dec-09-19	Upgrade	Citigroup	Neutral → Buy
Dec-05-19	Initiated	B. Riley FBR	Buy
Jun-07-19	Initiated	Stifel	Buy
Jun-05-19	Initiated	Cowen	Outperform

View All

X 4 Pharmaceuticals Inc Stock (XFOR) Latest News

Oct 09, 2026

X4 Pharmaceuticals Secures New $150 Million Term Loan - The Globe and Mail

Oct 09, 2026

Oct 08, 2026

XFOR: X4 Pharmaceuticals Inc Latest Stock Price, Analysis, News and Trading Ideas - Stocktwits

Oct 08, 2026

X4 Pharmaceuticals (XFOR) pairs a new loan with an approximately $78.7M debt payoff. - Stock Titan

Oct 08, 2026

Oct 07, 2026

No voting power is reported by Abigail P. Johnson in X4 Pharmaceuticals (XFOR)'s ownership amendment. - Stock Titan

Oct 07, 2026

Oct 02, 2026